文献速递白血病造血干细胞移植与细胞治疗

靶向CD33的双特异性及三特异性T细胞衔接器的制备及其对白血病细胞的细胞毒性

[Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

该研究构建并真核表达纯化了靶向CD33的双特异性T细胞衔接器(CD33-BiTE)及含CD80胞外段的三特异性T细胞衔接器(CD33-TriTE),体外实验显示两者均促T细胞增殖并呈浓度依赖性杀伤CD33阳性白血病细胞,CD33-TriTE促增殖更强且对PD-L1高表达白血病细胞杀伤更强。

要点

  • CD33-BiTE与CD33-TriTE均可与流式抗体竞争结合靶细胞表面CD33。
  • 共培养12天后T细胞分别扩增至33.89±19.46倍与81.56±23.62倍,TriTE更强(P<0.05)。
  • 两者均呈浓度依赖性杀伤CD33阳性白血病细胞,TriTE对PD-L1高表达细胞杀伤更强。

核心结论

  • 成功构建CD33-BiTE及CD33-TriTE表达载体并在真核细胞表达融合蛋白,体外实验支持两者促T细胞增殖活化及抗白血病作用。
  • CD33-TriTE较CD33-BiTE促T细胞增殖效果更强,且对PD-L1高表达的白血病细胞杀伤效果更强。

研究设计与样本

  • 研究构建抗CD33scFv-抗CD3scFv的双特异性T细胞衔接器(CD33-BiTE)及在其基础上加入CD80胞外段的三特异性T细胞衔接器(CD33-TriTE)表达载体。
  • 使用真核细胞表达系统表达蛋白并进行亲和层析纯化,通过体外实验检测两者对T细胞活化增殖及对白血病细胞杀伤功能的影响。

主要发现

  • 纯化得到的融合蛋白能与相同靶抗原流式抗体竞争结合于靶细胞表面。
  • CD33-BiTE及CD33-TriTE分别与人T细胞共培养12天后,T细胞数扩增至基线值的(33.89±19.46)倍和(81.56±23.62)倍,CD33-TriTE促T细胞增殖能力明显优于CD33-BiTE(P<0.05)。
  • 体外实验证实CD33-BiTE和CD33-TriTE均可增强T细胞对表达CD33白血病细胞的特异性杀伤作用,且在一定浓度范围内浓度越高杀伤作用越强。
  • 与CD33-TriTE相比,CD33-BiTE杀伤白血病细胞的同时增加其PD-L1表达,而CD33-TriTE对过表达PD-L1的Molm13细胞具有更强的杀伤作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the effect of CD33-targeted bi-specific and tri-specific T-cell engagers on T-cell proliferation and explore their cytotoxicity on leukemia cells. Methods: The CD33-targeted bi-specific T-cell engager (CD33-BiTE) and tri-specific T-cell engager (CD33-TriTE) expression vectors were successfully constructed and expressed through a eukaryotic cell expression system. CD33-BiTE and CD33-TriTE were purified by affinity chromatography. The effects of CD33-BiTE and CD33-TriTE on T cells were analyzed through in vitro experiments. Results: ① CD33-BiTE and CD33-TriTE were successfully constructed and purified and could compete with flow cytometry antibodies for binding to the target cells. ② After 12 days of co-culture with CD33-BiTE and CD33-TriTE, the number of human T cells were expanded to 33.89±19.46 and 81.56±23.62 folds, respectively. CD33-TriTE induced a stronger proliferation of T cells than CD33-BiTE (P<0.05) . ③ Both CD33-BiTE and CD33-TriTE induced specific dose-dependent cytotoxicity on CD33(+) leukemia cells. ④ Compared to CD33-TriTE, leukemia cells were prone to express PD-L1 when co-cultured with T cells and CD33-BiTE. CD33-TriTE induced powerful cytotoxicity on leukemia cells with high PD-L1 expression. Conclusion: CD33-BiTE and CD33-TriTE expression vectors were constructed, and fusion proteins were expressed in eukaryotic cells. Our results support the proliferative and activating effects of BiTE and TriTE on T cells. Compared to that of CD33-BiTE, CD33-TriTE induced a stronger proliferative effect on T cells and a more powerful cytotoxicity on leukemia cells with high PD-L1 expression. 目的: 研究靶向CD33抗原双特异性及三特异性T细胞衔接器对T细胞增殖及其抗白血病作用。 方法: 构建抗CD33scFv-抗CD3scFv的双特异性T细胞衔接器(CD33-BiTE)及在BiTE基础上加入CD80胞外段的三特异性T细胞衔接器(CD33-TriTE)表达载体,使用真核细胞表达系统表达蛋白并进行亲和层析纯化。检测CD33-BiTE及CD33-TriTE对T细胞活化增殖功能及对白血病细胞杀伤功能活性的影响。 结果: ①成功构建了CD33-BiTE及CD33-TriTE表达载体,在真核细胞中表达,纯化得到的融合蛋白能与相同靶抗原流式抗体竞争结合于靶细胞表面。②CD33-BiTE及CD33-TriTE分别与人T细胞共培养12 d后,T细胞数扩增至基线值的(33.89±19.46)倍和(81.54±23.62)倍,CD33-TriTE促T细胞增殖能力明显优于CD33-BiTE(P<0.05)。③体外实验证实CD33-BiTE和CD33-TriTE均可增强T细胞对表达CD33白血病细胞的特异性杀伤作用,且在一定浓度范围内,浓度越高,抗体的杀伤作用越强。④与CD33-TriTE相比,CD33-BiTE杀伤白血病细胞的同时增加其PD-L1表达,而TriTE对过表达PD-L1的Molm13细胞具有更强的杀伤作用。 结论: 该研究构建了CD33-BiTE及CD33-TriTE表达载体,并在真核细胞表达了融合蛋白,体外实验证实其促T细胞增殖活化的特性,并具有促T细胞抗白血病作用。其中CD33-TriTE较CD33-BiTE促增殖效果更强,且对PD-L1高表达的白血病细胞杀伤效果更强。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang T, Chen ML, Liu XY, et al. [Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35680594. doi:10.3760/cma.j.issn.0253-2727.2022.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。